IFN‐β has reported DDIs with other COVID‐19 therapies including chloroquine and hydroxychloroquine and with anakinra, sarilumab, and tocilizumab (Liverpool Drug Interaction Group, 2020). The gene discussed is IFNB1; the disease is COVID-19.